Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

Adjunctive Pascolizumab in Rifampicin-Susceptible Pulmonary Tuberculosis: Proof-of-Concept, Partially-Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Trial

Background Interleukin 4 (IL-4), increased in tuberculosis infection, may impair bacterial killing. Blocking IL-4 confers benefit in animal models. We evaluated safety and efficacy of pascolizumab (humanized anti-IL-4 monoclonal antibody) as adjunctive tuberculosis treatment.Methods Participants wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Paton, Nicholas I., Gurumurthy, Meera, Lu, Qingshu, Leek, Francesca, Kwan, Philip, Koh, Hiromi W. L., Molton, James, Mortera, Lalaine, Naval, Sullian, Abu Bakar, Zamzurina, Pang, Yong-Kek, Lum, Lionel, Lim, Tow Keang, Cross, Gail B., Lekurwale, Ganesh, Choi, Hyungwon, Au, Veonice, Connolly, John, Hibberd, Martin, Green, Justin A., Team, Pascolizumab TB Trial
Format: Article
Published: Oxford University Press 2024
Subjects:
QR Microbiology
R Medicine (General)
Online Access:http://eprints.um.edu.my/46996/
https://doi.org/10.1093/infdis/jiae104
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Universiti Malaya

Internet

http://eprints.um.edu.my/46996/
https://doi.org/10.1093/infdis/jiae104

Similar Items